Table 3.

Parameters for dose modifications of sorafenib^*

Toxicity	Sorafenib (prostate cancer)	Sorafenib (lung cancer)	Sorafenib plus bevacizumab
1st grade 2 AE	No change†	200 mg reduction	Hold - no reduction
Recurrent grade 2 AE	No change†	200 mg reduction	50% reduction
Grade 3 AE	200 mg reduction	50% reduction	50% reduction
Grade 4 AE	Discontinue	Discontinue**	Discontinue

AE = Adverse event

^†Dosing continued as long as patient tolerated treatment

^*all reductions and holds require temporarily halting sorafenib until AE resolves to grade 1 or less then restarting

^**grade 4 non-hematologic toxicity